secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001000694-23-000050
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q2 net income $58M on $424M revenue; SK bio partnership & Canada APA strengthen finances
--------------------------------------------------------------------------------

- Q2 total revenue $424M (up from $186M); net income $58M vs net loss $510M in Q2 2022.
- Updated FY 2023 revenue guidance to $1.3B-1.5B (from $1.4B-1.6B); combined R&D/SG&A cut to $313M from $398M.
- SK bioscience $85M equity investment at $13/share (59% premium); $195M manufacturing liability settled for $154M.
- Initiated FDA submission for updated XBB COVID vaccine; expect availability by September 2023.
- Reduced current liabilities by $864M in H1 2023; total reduction over $1B including SK bioscience deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/0001000694-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/nvax-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001000694-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer